In a previous study, increased phosphorylation of HER2 at tyrosine 1248 (pHER2Y1248) was an independent marker for poor clinical outcomes, including disease-free survival (DFS) and overall survival (OS), in breast cancer patients [10]. Here, ERBB2 is linked to breast carcinoma.